Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Animal TB "Tracker" To Speed Drug And Vaccine Studies
Johns Hopkins researchers have developed a novel way to monitor in real time the behavior of the TB bacterium in mouse lungs noninvasively pinpointing the exact location of Mycobacterium tuberculosis. The new monitoring system is expected to speed up what is currently a slow and cumbersome process to test the safety and efficacy of various TB drug regimens and vaccines in animals. Plans are already under way for developing a similar system to monitor TB disease in humans.
generic viagra online
Stroke Second Most Common Cause Of Death
It is no coincidence that the stroke theme is being given wide exposure at the ENS Congress. Stroke has become a major challenge for health policy and for medicine in general. It is now the second most common cause of death globally and the major cause of adult disability in the industrialized countries.
News of the day
European Scientific Committee Positive Recommendation From For A New Once Daily Mirapexin(R) Formulation For The Treatment Of Parkinson's Disease
Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin®/ Sifrol® (pramipexole), in all countries of the European Union, Norway, Iceland and Liechtenstein. The CHMP recommendation states that the new prolonged-release formulation is indicated for treatment of the signs and symptoms of idiopathic Parkinson"s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).
Diagnostics

World's First Cardiac Adult Stem Cell Patient Receives Infusion

Michael (Mike) Jones has become the world"s first recipient of adult cardiac stem cells to treat congestive heart failure. Jones" infusion on July 17 marks the world"s first phase-one FDA-approved clinical trial using adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of Louisville physicians at Jewish Hospital. During the infusion procedure, Jones was directly injected with his own cardiac stem cells into heart scar tissue using a minimally-invasive cardiac catheterization procedure, which reaches the heart through an artery in the patient"s leg. The 66-year-old, self-employed man continues to recover following the outpatient procedure. Mark Slaughter, M.D., Chief of the Division of Cardiothoracic Surgery at UofL and Director of the Heart Transplant and Mechanical Assist Device Program at Jewish Hospital, performed coronary artery bypass surgery on Jones on March 23. Jones suffered from congestive heart failure due to multiple blocked arteries that had resulted in permanent scarring of his heart muscle. During the procedure, Jones" cardiac stem cells were retrieved from a portion of his own atrium, the upper chamber of the heart. The tissue was then sent to Piero Anversa, of Harvard University and Brigham & Women"s Hospital in Boston, for processing and to grow cardiac stem cells from Jones" tissue. Jones" infusion procedure was performed at Jewish Hospital by Sohail Ikram, M.D., UofL Professor of Medicine and Director and Chief of Invasive and Interventional Cardiology at Jewish Hospital. Study leader Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL"s Institute for Molecular Cardiology said, "We continue to enroll patients in this first-of-its-kind clinical trial. We hope to help the heart regenerate its own tissue and improve heart function." Bolli is collaborating with a number of leaders in the field of cardiovascular and stem cell medicine for this clinical trial. The team will continue to evaluate Jones, as well as other patients who have enrolled in the clinical trial, for heart function and blood flow. In addition, the heart"s overall size and the size of the scar tissue will be measured. Since this is a phase-one clinical trial designed to test the treatment"s safety and feasibility, all patients enrolled in the trial will receive the cardiac stem cell therapy. Jewish Hospital


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009